deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03998683

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (G-PLUS)

A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis

Sponsor: Janssen-Cilag Ltd.

Conditions Psoriasis
Interventions Guselkumab 100 mg Placebo
Updated 25 times since 2019 Last updated: Dec 30, 2021 Started: Sep 3, 2019 Primary completion: Mar 2, 2021 Completion: Nov 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Psoriasis, this trial is completed. The trial is conducted by Janssen-Cilag Ltd. and has accumulated 25 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

▶ Show 20 earlier versions

  1. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  4. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  10. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  11. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  12. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  13. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  14. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  15. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  16. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  17. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  18. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  19. Sep 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE3

  20. Jul 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen-Cilag Ltd.
Data source: Janssen-Cilag Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Bentheim, Germany , Badalona, Spain , Bordeaux, France , Cagliari, Italy , Catania, Italy , Dresden, Germany , Dudley, United Kingdom , Frankfurt am Main, Germany , Hamburg, Germany , Leeds, United Kingdom and 14 more locations